Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Franse aandelen Terug naar discussie overzicht

Biophytis ontploft, Integragen en Theradiag next!

395 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 20 »» | Laatste | Omlaag ↓
  1. i know it 21 april 2020 10:23
    About BIOPHYTIS 
    Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuro muscular diseases.Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of BIO101 is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development in H2 2020.Sarconeos (BIO101) will also be developed as a treatment for Covid-19 (Coronavirus) for which the company has filed a clinical trial application with the French Regulatory Authority (ANSM).The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.

    5 Posts

    Aanta

  2. i know it 21 april 2020 10:37
    Correction - Biophytis launches a Public Offering of
    Share Subscription Warrants (BSA) with an Irreducible Priority
    Subscription Period for Existing Shareholders
    Paris (France), Cambridge (Etats-Unis), April 21 , 2020, 8:00 a.m. CEST – BIOPHYTIS (Euronext Growth
    Paris: ALBPS), today issued a correction of the press release issued on April 7, 2020, in order to
    consolidate important information relating to the offer to the public of Share Subscription Warrants
    (BSA) with an irreducible priority period for shareholders. This information was included until today in
    the Synthetic Information Document (DIS) posted on the Biophytis website on April 7, 2020. However,
    under this transaction, the Company was not subject to the publication of a DIS.

    Below is the corrected press release:
    Paris, (France), Cambridge (Massachusetts, United States), Biophytis SA (Euronext Growth Paris: ALBPS
    a clinical-stage biotechnology company specialized in the development of drug candidates for treatment
    of aged related diseases, especially neuromuscular diseases, announced on April 7, 2020 the launch of
    a public offering of 7,445,123 Share Subscription Warrants (BSA), which could be increased to 7,475,708
    BSA, by way of a public offering with an irreducible priority subscription period for existing shareholders,
    as well as an extension clause.
    Offering price
    The subscription price will be €0.06 per BSA for a total amount of €446,707.38 and €448,542.48 if the
    extension clause is exercised.
    BSA Offering
    The proposed issuance of the 7,445,123 BSA, to be subscribed in cash, will be carried out with
    shareholders’ preferential subscription rights removed. The Offer will include (i) a priority period for
    shareholders on an irreducible basis only, with 3 BSA for every 16 shares held as of April 8, 2020
    (operation settled at this date) (rounded to the higher unit if the number of shares is not a multiple of
    16) and (ii) an extension clause to increase the issue to 7,475,708 BSA.
    Shareholders registered as of April 8, 2020 (operation settled at this date) will benefit from a non-
    negotiable and non-transferable subscription priority period, from April 9, 2020 to April 21, 2020
    included at 12:00 p.m. (Paris time). As a result, all shares purchased on 7
    th and 8th April 2020 will not
    benefit from the priority period.
    As part of the priority period, the Company's shareholders will be able to subscribe on an irreducible
    basis to the extent of their shares in the Company's capital pursuant to the terms set out above. There
    are no plans to allow subscriptions on a reducible basis during the priority period.
    Unsubscribed BSAs will then be offered first to the Company's employees and executive officers within
    the limits of their requests. The Priority Period relates to the initial issuance amount, excluding the
  3. i know it 21 april 2020 10:39
    Waarom denken mensen dat het naar 0,30 cent gaat ??? Lees dan eens goed ! Voor bestaande aandeelhouders die er al langer inzitten hebben een voordeel. Maar op zeker boven de 2 euro eind van de week
  4. forum rang 5 RW1963 21 april 2020 12:21
    quote:

    i know it schreef op 21 april 2020 10:39:

    Waarom denken mensen dat het naar 0,30 cent gaat ??? Lees dan eens goed ! Voor bestaande aandeelhouders die er al langer inzitten hebben een voordeel. Maar op zeker boven de 2 euro eind van de week
    JAMMER!
    Je bent al weer flink gezakt t.o.v. een eerdere voorspelling.

    i know it 17 april 2020 17:19

    Oh ja tot ver over de 3 euro...
  5. [verwijderd] 21 april 2020 12:50
    quote:

    forumwatcher schreef op 21 april 2020 12:46:

    Mijn eerste post mocht er dan ook wel ééntje zijn met goed nieuws :)
    Haha thanks Forumwatcher!
    tot nu toe ziet het er goed uit, hoop dat je zelf ook profiteert ;)
395 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 20 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.286
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.463
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.956
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.489
Aedifica 2 832
Aegon 3.257 320.093
AFC Ajax 537 7.018
Affimed NV 2 5.762
ageas 5.843 109.779
Agfa-Gevaert 13 1.862
Ahold 3.536 73.983
Air France - KLM 1.024 34.348
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.774
Alfen 12 16.550
Allfunds Group 3 1.217
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 337
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.767
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.821 240.368
AMG 965 125.872
AMS 3 73
Amsterdam Commodities 303 6.522
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.163
Apollo Alternative Assets 1 17
Apple 5 316
Arcadis 251 8.623
Arcelor Mittal 2.024 318.668
Archos 1 1
Arcona Property Fund 1 267
arGEN-X 15 9.113
Aroundtown SA 1 176
Arrowhead Research 5 9.283
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.704
ASML 1.762 77.059
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.674
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 06 mei

    1. China inkoopmanagersindex diensten april
    2. PostNL Q1-cijfers
    3. Siemens Healthineers Q1-cijfers
    4. TKH Q1-cijfers
    5. Dui inkoopmanagersindex diensten april (def)
    6. EU inkoopmanagersindex diensten april (def) 52,9
    7. VK inkoopmanagersindex diensten april (def)
    8. EU producentenprijzen maart
    9. Tyson Foods Q1-cijfers
  2. 07 mei

    1. Japan inkoopmanagersindex diensten april
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht